Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Greenwich Lifesciences Inc

GLSI ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Micro Cap Analyst: BUY

Last Close

$16.80

▲ +2.56%

Market Cap $246.59M · Vol 33.40K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$246.59M

Micro Cap

Div Yield

N/A

EPS Growth

+3.15%

YoY

RSI (14)

73.73

Momentum

Beta

1.51

vs Market

52W High

$34.00

50.59% below

52W Low

$7.80

115.38% above

Volume

33.40K

Avg 45.16K

P/B

850.50

Price-to-book

ROE

N/A

Return on equity

Free Float

50.29%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Greenwich Lifesciences Inc (GLSI) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does GLSI pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+16.99%

-11.63%

-35.31%

-37.43%

YTD

-20.04%

+39.07%

+58.79%

-58.52%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-19,358,220.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-376.92% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	850.50
P/FCF	N/A
EPS Growth	+3.15%
Outstanding Shares	14.68M

Technical Indicators

50-Day SMA	$18.59
200-Day SMA	$20.51
RSI (14)	73.73
Beta	1.51
52-Week High	$34.00
52-Week Low	$7.80

Volume Today	33.40K
Avg Daily Volume (30D)	45.16K
Relative Volume	0.74x
Volatility (10D)	58.01
Volatility (30D)	95.18
Free Float	50.29%

Analyst Consensus

BUY

Current Price $16.80

Mean Target $57.00

52W Low$7.80 52W High$34.00

Current

Target

$7.80 $34.00

Current Analyst target

+239.29% upside potential · 2 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00V6PT8D6

ISINUS3968791083

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 14, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. It has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.